Aclarubicin (aclacinomycin A) is an anthracycline and topoisomerase II inhibitor that has been clinically tested against haematologic and solid tumors. Aclarubicin stabilizes topoisomerase I cleavage. Aclarubicin accumulates efficiently in the mitochondria of living human cells and leads to mitochondrial dysfunction. Aclarubicin inhibits reverse transcriptase, endothelin converting enzyme and collagenase, and is active against HIV.
| Molecular Formula | C42H53NO15 |
| References |
Beck WT et al (1994) Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells. Cancer Chemother Pharmacol. 34 Suppl:S14-8. Hori S et al (1977) Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gan 68:685 Iihoshi H et al (2017) Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells. Toxicol. Lett. 277:109 |